Skin ulcer
Drug research and approvals for skin ulcer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 213 studies of skin ulcer are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 213
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Silica-Based Wound Treatment (Curi01) Plus Standard Care Versus Standard Care Alone for Chronic Diabetic Foot WoundsNCT07937215 · Not applicable · Cutempa Medical AG · starts Aug 20, 2026
- Continuous Monitoring of Plantar Temperature Variations Using Connected Insoles and a Mobile Application for Diabetic…NCT07910721 · Not applicable · Solsius · starts Mar 10, 2026
- Comparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or…NCT07908641 · Phase 1 · Amgen · starts Nov 18, 2026
- Vacuum Compression Therapy and Tissue Oxygenation in Chronic Leg UlcersNCT07901517 · Not applicable · BTL Industries Ltd. · starts Oct 15, 2026
- Comparative Study of Combination Treatment of Bionerv E+ Versus Vitamin B Complex in Treatment of Diabetic…NCT07877948 · Not applicable · BREGO Life Sciences · starts Jul 22, 2025
- a Prospective, Multicenter, Randomized Controlled Trial, With a Non-randomized Sentinel Cohort, Evaluating the Efficacy…NCT07852338 · Phase 3 · Applied Biologics, LLC · starts Oct 8, 2026
- DiaFootCare to Promote Self-Care of Diabetic Foot Ulcers in OmanNCT07815275 · Not applicable · Oman Ministry of Health · starts Oct 13, 2026
- Evaluating the Impact of Vitamin D Supplementation on Healing Bed Sores in ICU.NCT07813975 · Not applicable · Maha Salah · starts Sep 6, 2026
- Urinary Bladder Matrix (UBM) RegistryNCT07805798 · Not reported · Integra LifeSciences Corporation · starts Oct 23, 2026
Approved 9
- BecaplerminPlatelet-derived growth factor receptor agonist
- Collagenase clostridium histolyticumCollagen hydrolytic enzyme
- Bromelains
- Cadexomer iodine
- Dextranomer
- Birch triterpenes
- Beremagene geperpavecCollagen alpha-1(VII) chain exogenous gene
- Dexpanthenol
- Trolamine
Phase 3 3
- Acetic acid
- TraferminFibroblast growth factor receptor 2 agonist
- Trypsin, crystallized
Phase 2 7
- Nitric oxideSoluble guanylate cyclase activator
- RimabotulinumtoxinbVesicle-associated membrane protein 2 inhibitor
- SildenafilPhosphodiesterase 5A inhibitor
- Pegylated carboxyhemoglobin (bovine)CO/O transfer
- Crilanomer
- Enoxolone
- Pantothenic acid
How its trials ended
74 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 17 whose ending is known, 12% met their primary endpoint, 6% missed it and 82% stopped early.
- Completed, result not reported2939%
- Ongoing1419%
- Status unknown1419%
- Stopped: other or unclear68%
- Stopped: enrollment or feasibility57%
- Met its primary endpoint23%
- Stopped: lack of efficacy23%
- Missed its primary endpoint11%
- Stopped: sponsor or business decision11%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA